Eli Lilly (NYSE:LLY) Soars: Analyst Raises Price Target on Robust Q1 Performance

Font: Financial Modeling Prep  • May 01, 2026

• Analyst raises price target for Eli Lilly (NYSE:LLY) to $1,344, suggesting a potential upside of approximately 39.77%.
• The pharmaceutical giant reported strong Q1 revenues of $19.8 billion, a 56% increase, and earnings per share (EPS) of $8.55, up 156%.
• Growth is primarily driven by surging sales of its GLP-1 drugs, Mounjaro and Zepbound, leading to raised 2026 revenue guidance of between $82 billion and $85 billion.

Eli Lilly is a global pharmaceutical company known for developing and selling a wide range of medicines. It has a strong focus on drugs for diabetes and obesity, with popular products like Mounjaro and Zepbound. The company operates in a highly competitive field, with Novo Nordisk as a primary rival, especially in the market for these treatments.

On May 1, 2026, an analyst from Morgan Stanley raised the price target for Eli Lilly to $1,344 from a previous target of $1,327. When the new target was set, the stock's price was $961.56. This new price target suggests a potential upside of approximately 39.77% from the price at the time of the update.

This analyst confidence is supported by the company's recent financial success. As highlighted by Zacks, Eli Lilly reported strong first-quarter results with revenues of $19.8 billion, a 56% increase from the prior year. Its earnings per share (EPS), or profit per share, was $8.55, marking a 156% year-over-year increase.

The impressive growth was driven by surging sales of its GLP-1 drugs, Mounjaro and Zepbound. Demand was strong globally, with U.S. revenues rising 43% to $12.1 billion and international revenues increasing by 81% to $7.7 billion. A 65% growth in sales volume was the main driver behind these figures.

Following the strong quarter, Eli Lilly raised its 2026 guidance, now expecting revenues between $82 billion and $85 billion. An analysis by GuruFocus also considers the stock "Modestly Undervalued," with a GF Value of $1302.77. The company holds a strong GF Score of 95 out of 100, suggesting a high potential for outperformance.